HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $395 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a $395 price target.

March 05, 2024 | 5:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals maintains a Buy rating and a $395 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100